Department of Internal Medicine

Hematology, Oncology and Blood &  Marrow Transplantation Faculty

Ali Naderi

Medical School:
Beheshti University of Medical Sciences, Tehran

Residency:
Wayne State University, Michigan

Hematology-Oncology Fellowship:
Mayo Clinic, Minnesota

Research Fellowship:
University of Cambridge, UK

Ali Naderi, M.D.
Associate Professor

I am a medical oncologist and physician-scientist with a special interest in the management of breast cancer. My research is focused on the identification of novel signaling pathways with therapeutic implications in breast cancer and my ultimate goal is the application of our laboratory findings to patient care. I currently have two main research projects in my group:

  1. Estrogen Receptor (ER)-negative Breast Cancer: We are investigating novel signaling pathways in ER-negative breast cancer. In particular we are interested in a subtype of ER-negative breast cancer that is characterized by the overexpression of androgen receptor (AR) and other steroid-response genes (Molecular Apocrine subtype). In this respect, we have identified a number of biologically significant feedback loops between the ErbB2-ERK signaling pathway and some of the key genes that characterize this subtype of breast cancer such as AR, FOXA1, and Prolactin-Induced Protein (PIP). Importantly, some of our findings have potential therapeutic implications and we are exploring the translational aspects of our projects by conducting investigator-initiated trials in patients with ER-negative breast cancer.
  2. BEX2 Pathway in Breast Cancer: We have identified BEX2 as a novel breast cancer gene that promotes survival and growth of breast cancer cells. BEX2 is overexpressed in about half of breast tumors and interacts with some of the key signaling pathways involved in breast tumorigenesis such as c-Jun/JNK, Protein Phosphatase 2A (PP2A), and NF-κB. We are currently characterizing the biochemical and functional aspects of the BEX2 pathway in breast cancer.

Honors, Awards, and Organizations

Recent Publications:

  1. Naderi A and Meyer M. Prolactin-Induced Protein mediates cell invasion and regulates Integrin signaling in estrogen receptor-negative breast cancer. Breast Cancer Research, 2012; 14(4): R111.
  2. Naderi A, Meyer M, Dowhan DH. Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer. Neoplasia, 2012; 14(4): 283-296.
  3. Naderi A, Liu J, Francis GD.  A feedback loop between BEX2 and ErbB2 mediated by c-Jun signaling in breast cancer. International Journal of Cancer, 2012; 130(1):  71-82.
  4. Naderi A, Chia KM, Liu J. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Breast Cancer Research, 2011; 13(2):R36.
  5. Chia KM, Liu J, Francis GD, Naderi A. A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasia, 2011; 13(2): 154-166.
  6. Naderi A, Microdeletion of 22q11.1 is associated with two cases of familial non-syndromic basal cell carcinoma. Cancer Genetics and Cytogenetics, 2010; 202(2): 133-135.
  7. Naderi A and Liu J. Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer. Cancer Letters, 2010; 298 (1): 74-87.
  8. Naderi A, Liu J, Hughes-Davies L. BEX2 has a functional interplay with c-Jun/JNK and p65/RelA in breast cancer. Molecular Cancer, 2010; 9(1):111.
  9. Naderi A, Liu J, Bennett IC. BEX2 regulates mitochondrial apoptosis and G1 cell cycle in breast cancer. International Journal of Cancer, 2010; 126(7):1596-1610.
  10. Naderi A and Hughes-Davies L. Nerve growth factor/nuclear factor-кB pathway as a therapeutic target in breast cancer. Journal of Cancer Research and Clinical Oncology, 2009;135 (2):211-6.
  11. Naderi A and Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia, 2008; 10(6):542-548.
  12. Cariati M, Naderi A, Brown JP, et al. Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like sub-population within the MCF7 breast cancer cell line. International Journal of Cancer, 2008; 122(2): 298-304.
  13. Naderi A, Teschendorff AE, Biegel J, et al.BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor /nuclear factor-κB inhibition of apoptosis in breast cancer cell lines. Cancer Research, 2007; 67(14): 6725-36.
  14. Naderi A, Teschendorff AE, Barbosa-Morais NL, et al. A gene-signature to predict survival in breast cancer across independent data sets. Oncogene, 2007; 26(10):1507-16.
  15. Chin SF, Wang Y, Thorne N, Teschendorff A, Pinder S, Vias M, Naderi A, et al. Using array-comparative genomic hybridizations to define molecular portraits of primary breast cancers. Oncogene, 2007; 26(13):1959-70.
  16. *Teschendorff AE, *Naderi A, Barbosa-Morais NL, et al. A consensus prognostic gene expression classifier for ER positive breast cancer. Genome Biology, 2006; 7(10):R101.
  17. Teschendorff AE, Naderi A, et al. PACK: Profile Analysis using Clustering and Kurtosis to find molecular classifiers in cancer. Bioinformatics, 2006; 22(18):2269-75.
  18. Naderi A, Ahmed AA, Wang Y., et al. Optimal amounts of fluorescent dye improve expression microarray results in tumor specimens. Molecular Biotechnology 2005; 30(2):151-154.
  19. Garcia MJ, Pole JC, Chin SF, Teschendorff A, Naderi A, et al. A 1Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene 2005; 24(33): 5235-45.
  20. Naderi A, Ahmed AA, Barbosa-Morais NL, et al. Expression microarray reproducibility is improved by optimizing purification steps in RNA amplification and labeling, BMC Genomics 2004; 5(1): 9.
  21. Sinclair CS, Rowley M, Naderi A, Couch FJ. The 17q23 amplicon and Breast Cancer, Breast Cancer Res Treat 2003; 78(3): 313-22.
  22. Naderi A, Couch FJ. BRCA2 and Pancreatic cancer. Int J Gastrointest Cancer. 2002; 31(1-3): 99-106.
  23. Sinclair CS, Adem C, Naderi A, et al. TBX2 is preferentially amplified in BRCA1 and BRCA2 related breast tumors. Cancer Research 2002; 62: 3587-3591.

Back to Hematology-Oncology Faculty List